# Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

> **NCT00904787** · PHASE1 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Relapsed or Refractory Hematological Malignancies

## Interventions

- **DRUG:** ENMD-2076

## Key facts

- **NCT ID:** NCT00904787
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-12
- **Final completion:** 2011-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2011-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904787, "Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00904787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*